Lung Cancer Clinical Trial
Early Detection of Lung Cancer
Summary
This research trial studies the long term follow-up for early detection of lung cancer in current or former smokers. Following up on smokers by collecting and analyzing specimens in the laboratory, performing chest computed tomography (CT) scans, as well as reviewing medical records may help doctors detect lung cancer at an earlier stage.
Full Description
PRIMARY OBJECTIVES:
I. To provide screening for lung cancer in an underserved and high risk population for lung cancer.
II. To collect clinical and demographic information and research bio specimens prospectively on high risk individuals.
III. To analyze the association between suspected lung cancer risk factors and outcomes such as pre-malignant lesions and diagnosis of lung cancer.
IV. To identify and validate biomarkers that are associated with lung cancer risk factors and premalignant lesions.
V. To assess the association between patient characteristics and test results to the genetic and histological characteristics of lung preinvasive lesions and cancers.
VI. To describe this high-risk cohort and to identify the patients eligible for future clinical trials (e.g. chemoprevention).
OUTLINE:
Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records.
Eligibility Criteria
Inclusion Criteria:
Current smoker or former smoker, if former smoker participants must have quit smoking within the past 15 years
>= 30 pack year of smoking history
Participant is uninsured
Exclusion Criteria:
History of diagnosis/treatment of lung cancer in the past 2 years
History of head/neck or esophageal cancer in the last 1 year
Inability to provide informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Nashville Tennessee, 37232, United States More Info
Principal Investigator
How clear is this clinincal trial information?